CHEMICALLY-MODIFIED ANTIGEN PREFERENTIALLY ELICITS INDUCTION OF TH1-LIKE CYTOKINE SYNTHESIS PATTERNS INVIVO

被引:97
作者
YANG, X
GIENI, RS
MOSMANN, TR
HAYGLASS, KT
机构
[1] UNIV MANITOBA, DEPT IMMUNOL, WINNIPEG R3E 0W3, MANITOBA, CANADA
[2] UNIV ALBERTA, DEPT IMMUNOL, EDMONTON T6G 2H7, ALBERTA, CANADA
关键词
D O I
10.1084/jem.178.1.349
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Differential activation of CD4+ T cell subsets in vivo leads to the development of qualitatively different effector responses. We identify an approach that allows selective activation of strongly Th1-dominated immune responses to protein antigens. Whereas in vivo administration of ovalbumin (OVA) induces cytokine synthesis that is neither Th1 nor Th2 dominated, administration of glutaraldehyde polymerized, high relative molecular weight OVA (OA-POL) leads to 20-fold increase in the ratio of interferon gamma (IFN-gamma)/IL-4 and IFN-gamma/IL-10 synthesis observed after short-term, antigen-mediated restimulation directly ex vivo. In contrast, concurrent in vivo administration of anti-IFN-gamma mAb and OVA or OA-POL results in marked increases in IL-4 and IL-10, and decreased IFN-gamma production, reflecting a polarization of the response towards a Th2-like pattern of cytokine synthesis. These observations may be useful in clinical settings including hypersensitivity, autoimmune diseases, and vaccine development where the ability to actively select specific patterns of cytokine gene expression would be advantageous.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 26 条
[1]   CONVERSION OF NONIMMUNOGENIC LOW-MOLECULAR WEIGHT RAGWEED COMPONENTS TO IMMUNOGENS FOR INDUCTION OF HOMOCYTOTROPIC ANTIBODY [J].
ATTALLAH, NA ;
KUROUME, T ;
SEHON, AH .
IMMUNOCHEMISTRY, 1975, 12 (6-7) :555-559
[2]   ESTABLISHMENT OF STABLE, CELL-MEDIATED-IMMUNITY THAT MAKES SUSCEPTIBLE MICE RESISTANT TO LEISHMANIA-MAJOR [J].
BRETSCHER, PA ;
WEI, GJ ;
MENON, JN ;
BIELEFELDTOHMANN, H .
SCIENCE, 1992, 257 (5069) :539-542
[3]  
BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687
[4]  
CHATELAIN R, 1992, J IMMUNOL, V148, P1182
[5]  
DEWIT D, 1993, J IMMUNOL, V150, P361
[6]  
FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511
[7]  
GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245
[8]  
GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750
[9]  
HAYGLASS KT, 1991, IMMUNOLOGY, V73, P407
[10]  
HAYGLASS KT, 1991, J IMMUNOL, V147, P2455